Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2022 Earnings Results

Rhythm Pharmaceuticals Misses on EPS, Stock Up 13.82%

Rhythm Pharmaceuticals reported a wider-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 13.82%, likely due to positive sentiment around their ongoing pipeline developments and management's focus on future milestones. Investors may be optimistic about the company's long-term potential despite the EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.89	N/A	-13.09%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their long-term strategy despite the EPS miss. They are focused on future developments and maintaining momentum.

Management highlighted ongoing efforts to advance their pipeline.

They emphasized the importance of upcoming clinical milestones.

Rhythm Pharmaceuticals Misses on EPS, Stock Up 13.82%

Key numbers

Management commentary

Rhythm Pharmaceuticals, Inc.

More earnings this week

Rhythm Pharmaceuticals Misses on EPS, Stock Up 13.82%

Key numbers

Management commentary